Atlas Trials

A Prospective, One-arm and Open Clinical Study of Obinutuzumab in the Treatment of Immune Thrombocytopenia

Clinical trial NCT05995054 · RECRUITING

Trial details

NCT number
NCT05995054
Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Immune ThrombocytopeniaTreatment
Start date
2023-08-28
Primary completion
2025-08-01
Enrollment
110

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.